HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Consensus Recommendation of “Hold” by Analysts

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have earned an average rating of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $15.30.

Several research firms recently issued reports on HCM. Bank of America reduced their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Weiss Ratings cut shares of HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 29th. Finally, Morgan Stanley set a $13.60 target price on shares of HUTCHMED in a research note on Thursday, May 28th.

Hedge Funds Weigh In On HUTCHMED

Hedge funds and other institutional investors have recently modified their holdings of the company. Amundi grew its stake in shares of HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after purchasing an additional 8,916 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in HUTCHMED in the first quarter worth $365,000. State Street Corp boosted its holdings in HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares in the last quarter. Renaissance Technologies LLC increased its position in HUTCHMED by 3.0% during the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $1,798,000 after purchasing an additional 3,900 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in HUTCHMED by 157.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after purchasing an additional 34,248 shares during the period. 8.82% of the stock is owned by institutional investors.

HUTCHMED Trading Up 0.8%

Shares of HCM traded up $0.09 during trading hours on Friday, hitting $11.07. The company had a trading volume of 37,482 shares, compared to its average volume of 47,000. The stock’s 50 day moving average price is $11.45 and its 200 day moving average price is $13.48. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. HUTCHMED has a 52-week low of $9.77 and a 52-week high of $19.50.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.